

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs.

Sponsors will have the opportunity to exhibit with a company stand during the meeting.

Please note that amongst the list of sponsors, GSK did provide funds towards the cost of the meeting, however they will not be in attendance at the event.

#### Premium Sponsors



#### Standard Sponsors



# UK Myeloma Society Autumn Day

## UK Myeloma Society at 25: Achievements and Future Directions

Thursday 14<sup>th</sup> November 2024

Hybrid Event from the Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT

*Register to attend in person or watch a live stream*

**Joint Chairs: Dr Matthew Jenner** (University Hospital Southampton)

**Dr Firas Al-Kaisi** (University Hospitals of Derby and Burton)

09.00 *Registration, coffee & exhibition*

09.25 Welcome and introduction

09.30 UK practice updates

### 25 Years of UK Myeloma Society

09.50 College of Myeloma UK - reflections on careers in myeloma

10.05 College of Myeloma UK - reflections on careers in myeloma

10.20 *Coffee break & exhibition*

### 10.50 EHA / IMS Abstract Award Winners

Multiple myeloma causes changes in fatty acid metabolism in tumour associated macrophages via a fatp2 dependent mechanism

Dissecting the contribution of circulating proteins to multiple myeloma risk: a mendelian randomization study

Barriers to the implementation of bispecific antibodies for patients with relapsed/refractory myeloma: results of a UK National Survey

Are participants of myeloma trials representative of the patient population? Audit data from a large haematology centre in the UK

### Michael Morley Lecture

11.25 Progress in myeloma over the last 25 years and directions for the future

12.25 *Lunch, networking & exhibition*

13.15 AGM

### Bench to Bedside and Back Again

13.30 A translational journey of studying drugs and disease

**Dr Neil Rabin**

*University College London Hospitals*

**Professor Gordon Cook**

*St James's University Hospital, Leeds*

**Professor Jamie Cavenagh**

*St Bartholomew's Hospital, London*

**Sarah Henshaw**

*Nottingham University Hospitals*

**Rosie Taylor**

*University of East Anglia*

*UKMS/Menarini Stemline IMS Bursary Winner*

**Dr Lucy Goudswaard**

*University of Bristol*

*UKMS/Sanofi IMS Bursary Winner*

**May Low**

*University College London Hospitals*

*UKMS/The Binding Site IMS Bursary Winner*

**Chantelle Hughes**

*University College London Hospitals*

*UKMS/Johnson & Johnson IMS Bursary Winner*

**Professor Michele Cavo**

*University of Bologna*

**Professor Anjan Thakurta**

*University of Oxford*

## Parallel Sessions: Clinical and Scientific

### UKMRA Science Forum *See next page for programme*

### PORTLAND ROOM

14.00 Science Forum starts

16.30 Science Forum ends

*If you wish to attend this session, please ensure that you select the appropriate package when completing your registration. Places are limited.*

### Clinical Session: Shaping the Next 3 to 5 Years: Key Priorities

Treatment pathway

14.00 England

**Professor Martin Kaiser**

*Royal Marsden Hospital*

14.10 Wales

**Dr Ceri Bygrave**

*University Hospitals of Wales*

14.15 Scotland

**Dr Jennifer Travers**

*Beatson West of Scotland Cancer Centre*

14.20 Northern Ireland

**Dr Sarah Lawless**

*Belfast City Hospital*

14.30 Cross-organisational collaboration

**Eric Low, OBE**

*Consilium Scientific*

14.45 Patient priorities and inclusion

**Shelagh McKinlay & Sophie Castell**

*Myeloma UK*

**Louise Martinez**

*Patient Representative, Reading*

15.05 Panel discussion

15.20 *Coffee break & exhibition*

### The Next 25 Years in Myeloma: What Does the Future Hold?

15.50 Diagnostics/monitoring

**Professor Gordon Cook**

*St James's University Hospital, Leeds*

16.00 Imaging

**Dr Tim Bray**

*University College London Hospitals*

16.10 Treatment

**Dr Rakesh Popat**

*University College London Hospitals*

16.20 Data science and AI

**Professor Geoff Hall**

*Chief Clinical Data Officer*

*Health Data Research UK*

16.30 Panel discussion

16.40 *Close*

### Registration:

Standard Fee (until 31 October)

£70 (£50 for Scientists, Nurses & Pharmacists)

Late Fee (from 1 November)

£120 (£85 for Scientists, Nurses & Pharmacists)

**Registration now open at [www.collaborativeconferences.co.uk/ukmsociety](http://www.collaborativeconferences.co.uk/ukmsociety)**

*Online registration for this meeting is for healthcare professionals only*

**Enquiries: Please contact Alex - [alex@collaborativeconferences.co.uk](mailto:alex@collaborativeconferences.co.uk)**

The UK Myeloma Society exists to improve the care of myeloma patients through education and the promotion of trials

### Premium Sponsors



### Standard Sponsors



*All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs.*

*Sponsors will have the opportunity to exhibit with a company stand during the meeting.*

*Please note that amongst the list of sponsors, GSK did provide funds towards the cost of the meeting, however they will not be in attendance at the event.*



## UKMRA Science Forum at the UK Myeloma Society Autumn Day

Thursday 14<sup>th</sup> November 2024

Cavendish Conference Centre - PORTLAND ROOM

**Leading the Session:**

**Dr Shelly Lawson** (*Sheffield*) and **Dr Sarah Gooding** (*Oxford*)

|       |                                                                                                                   |                                                            |
|-------|-------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|
| 14.00 | Effect of cholesterol on multiple myeloma pathogenesis                                                            | <b>Beatriz Gamez Molina</b><br><i>University of Oxford</i> |
| 14.15 | Investigating the effect of myeloma disease development from precursors on NK cells and their function            | <b>Elise Rees</b><br><i>University College London</i>      |
| 14.30 | Evidence for peri-lacunar remodelling and altered osteocyte lacuno-canalicular network in mouse models of myeloma | <b>Rebecca Andrews</b><br><i>University of Sheffield</i>   |
| 14.45 | Breaking silence: unveiling structural variants in compact heterochromatin regions of the myeloma genome          | <b>Aneta Mikulasova</b><br><i>Newcastle University</i>     |
| 15.00 | Epigenetic combination therapies to overcome IMiD resistance                                                      | <b>Yigen Li</b><br><i>Institute of Cancer Research</i>     |
| 15.15 | Q&A panel discussion                                                                                              |                                                            |
| 15.30 | <i>Coffee break</i>                                                                                               |                                                            |
| 15.45 | Networking / collaboration session (speed networking)                                                             |                                                            |
| 16.30 | Summary and close                                                                                                 |                                                            |

### Premium Sponsors



### Standard Sponsors



*All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs.*

*Sponsors will have the opportunity to exhibit with a company stand during the meeting.*

*Please note that amongst the list of sponsors, GSK did provide funds towards the cost of the meeting, however they will not be in attendance at the event.*